Global Biopharmaceuticals Contract Manufacturing Market Forecasted to Reach $33.99 Billion in Value by 2029

 Grab 20% Off With Code ONLINE20 On Global market Reports — Evaluate Global Trends, Market Risks, and Competitive Intelligence

 

 What Is the Estimated Market Size and CAGR of the Biopharmaceuticals Contract Manufacturing Market for the Period 2025–2029?
 The biopharmaceuticals contract manufacturing market size has grown rapidly in recent years. It will grow from $20.13 billion in 2024 to $22.22 billion in 2025 at a compound annual growth rate (CAGR) of 10.4%. The growth in the historic period can be attributed to increased biopharmaceutical development, cost efficiency and risk mitigation, growing pipeline of biologics, globalization of biopharmaceutical industry, flexible manufacturing solutions.
 
 The biopharmaceuticals contract manufacturing market size is expected to see rapid growth in the next few years. It will grow to $33.99 billion in 2029 at a compound annual growth rate (CAGR) of 11.2%. The growth in the forecast period can be attributed to increasing outsourcing trends, biosimilar development, shorter time-to-market requirements, global market expansion, focus on specialized services. Major trends in the forecast period include technological integration, outsourcing expansion beyond large molecules, advanced manufacturing technologies adoption, focus on quality and compliance, rise of biosimilars manufacturing,.
 
 Get your free report sample today:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=10181&type=smp
 
 Which Factors Are Contributing Most to the Expansion of the Biopharmaceuticals Contract Manufacturing Market?
 The growing demand for personalized medicine is expected to propel the growth of the biopharmaceutical contract manufacturing market going forward. Personalized medicine refers to a customized healthcare approach that takes into account individual patient traits, including genetics, environment, and lifestyle, to enhance treatment effectiveness and outcomes. The increasing demand for personalized medicine is driven by several factors, including advancements in genomics, patient empowerment, and improved treatment efficacy. Contract manufacturers can create tailored production processes designed to fulfill the specific requirements of personalized therapies, accommodating small batch sizes and unique formulations. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the FDA approved 16 novel personalized therapies for patients with rare diseases in 2023, compared to six in 2022. Therefore, the growing demand for personalized medicine drives the growth of biopharmaceutical contract manufacturing market.
 
 What Are the Emerging Segments Driving Growth in the Biopharmaceuticals Contract Manufacturing Market?
 The biopharmaceuticals contract manufacturing market covered in this report is segmented — 
 
 1) By Product: Biologics, Monoclonal Antibodies (MABs), Recombinant Proteins, Vaccines, Antisense, RNAi, And Molecular Therapy, Biosimilars
 2) By Source: Mammalian, Non-mammalian
 3) By Service: Process Development, Fill And Finish Operations, Analytical And QC studies, Packaging
 4) By Application: Clinical, Commercial
 
 Subsegments:
 1) By Biologics: Enzymes, Hormones, Antibodies
 2) By Monoclonal Antibodies (MABs): Human MABs, Chimeric MABs, Murine MABs
 3) By Recombinant Proteins: Insulin, Growth Factors, Cytokines
 4) By Vaccines: Live Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines
 5) By Antisense, RNAi, And Molecular Therapy: Antisense Oligonucleotides, RNA Interference Products, Gene Therapies
 6) By Biosimilars: Biosimilar Monoclonal Antibodies, Biosimilar Insulin, Biosimilar Growth Hormones
 
 What Are the Current Trends Influencing the Biopharmaceuticals Contract Manufacturing Market?
 Product innovations are a key trend gaining popularity in the biopharmaceuticals contract manufacturing market. Major companies operating in the biopharmaceutical contract manufacturing market are developing innovative products to sustain their position in the market. For instance, in February 2023, Thermo Fisher Scientific, a US-based biotechnology research company, and Elektrofi, a US-based biotechnology company specializing in drug formulation and delivery innovations, entered into a strategic contract manufacturing agreement to support the commercial production of Elektrofi’s ground-breaking ultra-high concentration subcutaneous products. Elektrofi’s proprietary microparticle technology enables small-volume injections of biologics such as monoclonal antibodies, therapeutic proteins, and other large-molecule medications important for human health. Elektrofi’s platform technology allows patients to self-inject medicines at home rather than in a hospital setting, overcoming the difficulties of administering biologic-based medications.
 
 Which Companies Hold a Prominent Position in the Biopharmaceuticals Contract Manufacturing Market?
 Major companies operating in the biopharmaceuticals contract manufacturing market include Boehringer Ingelheim GmbH, Lonza Group Ltd., Inno Biologics Sdn Bhd, Rentschler Biopharma SE, Samsung Biologics Co. Ltd., AGC Biologics, ProBioGen AG, FUJIFILM Diosynth Biotechnologies, Thermo Fisher Scientific Inc., Binex Co. Ltd., AbbVie Inc., Catalent Inc, Pfizer Inc., Merck KGaA, Pressure BioSciences, Novartis International AG, Cambrex Corporation, Emergent BioSolutions Inc., JRS Pharma GmbH & Co. KG, WuXi Biologics, Siegfried Holding AG, Toyobo Co. Ltd., ADMA Biologics Inc., UCB S.A., AstraZeneca PLC, Johnson & Johnson, Takeda Pharmaceutical Company Limited, Shire Pharmaceuticals LLC, Baxter International Inc., Becton Dickinson and Company, Polyphor Ltd., Patheon Inc., Alcami Corporation 
 
 Get the detailed biopharmaceuticals contract manufacturing market report today
 https://www.thebusinessresearchcompany.com/report/biopharmaceuticals-contract-manufacturing-global-market-report
 
 What Are the Fastest-Growing Regions in the Biopharmaceuticals Contract Manufacturing Market?
 North America was the largest region in the biopharmaceutical contract manufacturing market in 2024.Asia-Pacific is expected to be the fastest-growing region in the global biopharmaceuticals contract manufacturing market forecast period. The regions covered in the biopharmaceuticals contract manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
 
 Contact Us:
 
 The Business Research Company 
 
 https://thebusinessresearchcompany.com/ 
 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 
 Email: info@tbrc.info 
 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company